Gross Profit Analysis: Comparing Bristol-Myers Squibb Company and Supernus Pharmaceuticals, Inc.

Pharma Giants: Gross Profit Trends from 2014 to 2023

__timestampBristol-Myers Squibb CompanySupernus Pharmaceuticals, Inc.
Wednesday, January 1, 201411947000000116287000
Thursday, January 1, 201512651000000136004000
Friday, January 1, 201614481000000203017000
Sunday, January 1, 201714710000000287023000
Monday, January 1, 201816014000000393541000
Tuesday, January 1, 201918067000000376095000
Wednesday, January 1, 202030745000000467938000
Friday, January 1, 202136445000000504714000
Saturday, January 1, 202236022000000580017000
Sunday, January 1, 202334313000000523742000
Monday, January 1, 202436351000000
Loading chart...

Unleashing the power of data

Gross Profit Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Bristol-Myers Squibb Company and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Bristol-Myers Squibb, a titan in the industry, showcased a robust growth trajectory, with gross profits soaring by nearly 187% over the decade. In contrast, Supernus Pharmaceuticals, a smaller player, experienced a commendable 350% increase, albeit from a much smaller base.

Key Insights

  • Bristol-Myers Squibb: The company saw a significant leap in 2020, with profits peaking in 2021 at approximately 36 billion, before a slight dip in 2023.
  • Supernus Pharmaceuticals: Despite its smaller scale, the company consistently grew, reaching its highest gross profit in 2022.

These trends highlight the dynamic nature of the pharmaceutical sector, where both giants and emerging companies can thrive.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025